GlaxoSmithKline managed to notch some wins during the pandemic-challenged year of 2020, but COVID-19 took its toll—not only on the British pharma's finance...

Eli Lilly is counting on its new meds—including rheumatoid arthritis drug Olumiant—to drive growth in the years to come. With a new trial win in the autoim...

Heading into last year, Novavax had just $80 million in cash and a “financial operating horizon” of six months, its CEO said this week. That's all changed. Nowadays,...

Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis...

After an unceremonious exit from the COVID-19 vaccine race, Merck & Co. has been sizing up opportunities to lend its expertise to the fight. Now, ...

In the kinase inhibitor class of breast cancer drugs, Pfizer’s Ibrance has held a strong lead in market share—and sales—over Eli Lilly’...

After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds i...

Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help brin...

AbbVie’s Rinvoq just recently reported a pivotal trial win in ulcerative colitis, and one team of analysts is already drawing a rosy future for the next-gen immunolo...